Conteltinib has effective anti-tumor activity not only in ALK TKI-naïve, advanced ALK-positive NSCLC patients (ORR=64.1%), but also in patients who received crizotinib previously (ORR=33.3%). The gene discussed is ALK; the disease is non-small cell lung carcinoma.